Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients

Drug Resistance Updates

Volumn 4, Issue 1, 2001, Pages 22-28

  Weisberg, Ellen ^a   Griffin, James D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OROSOMUCOID; UNCLASSIFIED DRUG; VERAPAMIL;

CANCER REGRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; HUMAN; LEUKEMIA; MODEL; ONCOGENE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0035064790     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0180     Document Type: Article

References (51)

1. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
2. Structural organization of the bcr gene and its role in the Ph' translocation
3. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
4. BCR-ABL gene variants
5. The p190, p210, and p230. forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
6. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins
7. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line
8. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
9. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase
10. Signal transducer and activator of transcription (STAT5) activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
11. Transformation of hematopoietic cells by BCR/ABL requires activation of a Pl-3k/Akt-dependent pathway
12. Inteferon alpha in the treatment of chronic myelogenous leukemia
13. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
14. Chronic myelogenous leukemia: Biology and therapy
15. Bone marrow transplantation for chronic myelogenous leukemia
16. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
17. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
18. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
19. ARG tyrosine kinase activity is inhibited by ST1571
20. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibiton
21. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
22. Morphologic findings in peripheral blood and bone marrow of ST1571-treated chronic myelogenous leukemia patients
23. Clinical activity of an ABL-tyrosine kinase inhibitor (ST1571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation
24. Clinical and cytogenetic complete remission (CR) with ST1571 therapy in a patient with Philadelphia chromosome (Ph)-opositive chronic myeloid leukemia (CML) in T-cell lymphoid blastic phase (BP)
25. A phase II study of ST1571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase and interferon refractory patients
26. A Phase II study to determine the safety and antileukemic effects of ST1571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
27. Phase II study of ST1571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
28. A Phase II study to determine the safety and antileukemic effects of ST1571 in adult patients with Philadelphia chromosome positive acute leukemias
29. Structural mechanism for ST1-571 inhibition of Abelson tyrosine kinase
30. A point mutation in the ABL catalytic domain induces resistance to the tyrosine kinase inhibitor ST1571
31. Analysis of the structural basis of specificity of inhibition of the ABL kinase by ST1571
32. Mechanism of resistance to the ABL tyrosine kinase inhibitor ST1571 in BCR/ABL-transformed hematopoietic cell lines
33. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: Diverse mechanisms of resistance
34. Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification
35. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein
36. Downregulation of BCR/ABL expression and kinase activity but reciprocally increased phosphorylation of specific proteins in ST1571 resistant K562 cells: Edidence for the involvement of other tyrosine phosphoproteins in signaling and survival
37. Efficacy of ST1571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
38. Response of ST1571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors
39. The MDRI-positive K562/DOX cell line is resistant to the ABL tyrosine kinase inhibitor ST1571
40. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor ST1571
41. Elevated levels of the plasma glycoprotein alpha-1-acid glycoprotein (AGP) in patients with CML should not mediate resistance to ST1571
42. Characterization of the clinical response to ST1571: Biochemical evaluation of responsive and resistant advanced stage chronic myelogenous leukemia patients
43. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an ABL-specific kinase inhibitor
44. The tyrosine kinase inhibitor ST1571 prolongs survival in a murine model of chronic myelogenous leukemia
45. Relapse in Ph+ leukemia patients treated with an ABL-specific kinase inhibitor is associated with reactivation of BCR/ABL
46. ST1571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation
47. Detection of resistance to ST1571 in patients with BCR/ABL positive acute leukemia and chronic myeloid leukemia (CML) blast crisis
48. A significant proportion of CD34+ CML progenitor cells survive exposure to ST1-571 independent of their position in cell cycle
49. Mechanisms of resistance to the tyrosine kinase inhibitor ST571 and prospects for circumvention by combination with conventional chemotherapeutic agents
50. Dose response effect and time to clinical response in patients with interferon refractory CML treated with ST1571
51. ST1-571 induces mixed chimerism in patients relapsing in blastic transformation after allogeneic stem cell transplantation for chronic myeloid leukemia